Jonathan Zalevsky
Net Worth
Last updated:
What is Jonathan Zalevsky net worth?
The estimated net worth of Dr. Jonathan Zalevsky is at least $17,618,572 as of 19 Dec 2024. He owns shares worth $8,747,951 as insider, has earned $1,730,621 from insider trading and has received compensation worth at least $7,140,000 in Nektar Therapeutics.
What is the salary of Jonathan Zalevsky?
Dr. Jonathan Zalevsky salary is $1,190,000 per year as Chief R&D Officer in Nektar Therapeutics.
How old is Jonathan Zalevsky?
Dr. Jonathan Zalevsky is 50 years old, born in 1975.
What stocks does Jonathan Zalevsky currently own?
As insider, Dr. Jonathan Zalevsky owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | Chief R&D Officer | 326,904 | $26.76 | $8,747,951 |
What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Jonathan Zalevsky insider trading
Nektar Therapeutics
Dr. Jonathan Zalevsky has made 24 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 51,115 units of NKTR stock worth $48,048 on 19 Dec 2024.
The largest trade he's ever made was exercising 73,716 units of NKTR stock on 18 Aug 2022. As of 19 Dec 2024 he still owns at least 326,904 units of NKTR stock.